{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T09:17:13Z","timestamp":1649150233956},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","theclinics.com","gastro.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.gtc.2014.05.013","type":"journal-article","created":{"date-parts":[[2014,8,8]],"date-time":"2014-08-08T06:32:11Z","timestamp":1407479531000},"page":"619-630","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Update on Ustekinumab for the Treatment of Crohn's Disease"],"prefix":"10.1016","volume":"43","author":[{"given":"Yvette","family":"Leung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remo","family":"Panaccione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gtc.2014.05.013_bib1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2249.1990.tb03334.x","article-title":"Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine","volume":"81","author":"MacDonald","year":"1990","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.gtc.2014.05.013_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0140-6736(98)03339-X","article-title":"Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease","volume":"353","author":"Schreiber","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2014.05.013_bib3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A\u00a0short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.013_bib4","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2014.05.013_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.013_bib6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.013_bib7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.013_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.013_bib9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ibd.20177","article-title":"Infliximab dose intensification in Crohn's disease","volume":"13","author":"Regueiro","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gtc.2014.05.013_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.gtc.2014.05.013_bib11","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/gut.2008.155812","article-title":"Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort","volume":"58","author":"Schnitzler","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.gtc.2014.05.013_bib12","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/ajg.2008.88","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2014.05.013_bib13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gtc.2014.05.013_bib14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2036.2010.04360.x","article-title":"Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease","volume":"32","author":"Hanauer","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gtc.2014.05.013_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187152812800392805","article-title":"The IL23\/Th17 pathway as a therapeutic target in chronic inflammatory diseases","volume":"11","author":"Toussirot","year":"2012","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.gtc.2014.05.013_bib16","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0016-5085(97)70128-8","article-title":"Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells","volume":"112","author":"Monteleone","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.013_bib17","first-page":"823","article-title":"Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease","volume":"150","author":"Parronchi","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.gtc.2014.05.013_bib18","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A\u00a0genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.gtc.2014.05.013_bib19","doi-asserted-by":"crossref","first-page":"7234","DOI":"10.4049\/jimmunol.165.12.7234","article-title":"Up-regulation of the IL-12 receptor beta 2 chain in Crohn's disease","volume":"165","author":"Parrello","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.gtc.2014.05.013_bib20","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.gtc.2014.05.013_bib21","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A\u00a0randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gtc.2014.05.013_bib22","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/ajg.2009.454","article-title":"Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease","volume":"104","author":"Toedter","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2014.05.013_bib23","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.013_bib24","unstructured":"A study to evaluate the safety and efficacy of ustekinumab in patients with moderately to severely active Crohn's disease who have failed or are intolerant to tumor necrosis factor (TNF) antagonist therapy (UNITI-1). Available at: http:\/\/clinicaltrials.gov\/show\/NCT01369329.http:\/\/clinicaltrials.gov\/show\/NCT01369329. Accessed April 24, 2014."},{"key":"10.1016\/j.gtc.2014.05.013_bib25","unstructured":"A study to evaluate the safety and efficacy of ustekinumab in patients with moderately to severely active Crohn's disease (UNITI-2). Available at: http:\/\/clinicaltrials.gov\/show\/NCT01369342.http:\/\/clinicaltrials.gov\/show\/NCT01369342. Accessed April 24, 2014."},{"key":"10.1016\/j.gtc.2014.05.013_bib26","unstructured":"A study to evaluate the safety and efficacy of ustekinumab maintenance therapy in patients with moderately to severely active Crohn's disease (IM-UNITI). Available at: http:\/\/clinicaltrials.gov\/show\/NCT01369355.http:\/\/clinicaltrials.gov\/show\/NCT01369355. Accessed April 25, 2014."},{"key":"10.1016\/j.gtc.2014.05.013_bib27","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2014.05.013_bib28","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2014.05.013_bib29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.gtc.2014.05.013_bib30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.gtc.2014.05.013_bib31","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.gtc.2014.05.013_bib32","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.gtc.2014.05.013_bib33","first-page":"864","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials","volume":"306","author":"Ryan","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.gtc.2014.05.013_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.crohns.2014.02.004","article-title":"Demyelination in a patient receiving ustekinumab for refractory Crohn's disease","author":"Badat","year":"2014","journal-title":"J\u00a0Crohns Colitis"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855314000703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889855314000703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T22:56:51Z","timestamp":1538348211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889855314000703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0889855314000703"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2014.05.013","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Ustekinumab for the Treatment of Crohn's Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2014.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}